Donor-derived CD7 CAR-T Cells for Pediatric and Adult Relapsed/Refractory T-ALL/LBL

2025.10.04

Blood

Publication Brief

Phase 2 trial establishing donor-derived CD7 CAR-T as a highly effective salvage therapy for both pediatric and adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma.

Abstract

This phase 2 trial assessed CD7 chimeric antigen receptor (CAR) T cells derived from previous transplant or newly HLA-matched donors for relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Early termination from departmental closure yielded 55 treated patients out of 70 planned. Within 3 months, 89% of treated patients achieved best overall response of partial remission or better. A total of 19 received stem cell transplantation at a median of 1.3 (range, 1.0-10.6) months. After a 26.3-month median follow-up, median event-free survival was 5.0 months (95% confidence interval [4.1-8.4]), with median 8.5-month overall survival (95% confidence interval [6.1-15.6]). No deaths occurred within 30 days; adverse events included cytokine release syndrome in 87% at grades 1 to 2 and 11% at grade 3 and neurotoxicity in 9% at grade 1. In addition, graft-versus-host disease was in 38% at grades 1 to 2 and 2% at grade 3. Grades 1 and 2 infections occurred in 29%. Cytopenias occurred in 4% at grade 2 and 96% at grades 3 and 4. After 30 days, grades 3 to 5 adverse events included cytopenias (grade 3 in 24%; grade 4 in 67%), infections (grade 3 in 9%; grade 4 in 5%; grade 5 in 9%), graft-versus-host disease (grade 3 in 4%; grade 5 in 4%), thrombotic microangiopathy (grade 5 in 4%), and hepatic failure (grade 5 in 2%). Furthermore, 11 encountered nonrelapse mortality after 30 days, representing 20% of treated patients and 35% of responders without consolidatory transplantation. Although effective at inducing remission, death in remission beyond 30 days is a concern. This trial was registered at www.clinicaltrials.gov as #NCT04689659.

Journal: Blood. 2025 Dec 4.

Volume / Pages: 146(23):2745-2757

DOI: 10.1182/blood.2025029299

PubMed: PubMed: 40712157

Donor-derived CD7 CAR-T Cells for Pediatric and Adult Relapsed/Refractory T-ALL/LBL

Publication Brief

Abstract

Related Picks

Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia

BCMA/GPRC5D Bispecific CAR T-cell Therapy for R/R Multiple Myeloma with Extramedullary Disease

Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Anti-GPRC5D CAR T-cell Therapy as Salvage Treatment in Patients with Progressive Multiple Myeloma after Anti-BCMA CAR T-cell Therapy

Prominent Efficacy and Good Safety of Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia

Phase I trial validating a simplified autologous CD7 CAR-T manufacturing process without T-cell pre-selection, expanding accessibility for pediatric r/r T-ALL patients

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial

Sequential CD19 and CD22 Chimeric Antigen Receptor T-cell Therapy for Childhood Refractory or Relapsed B-cell Acute Lymphocytic Leukaemia

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

Allogenic and Autologous Anti-CD7 CAR-T-cell Therapies in Relapsed or Refractory T-cell Malignancies

Long-term Follow-up of Donor-derived CD7 CAR T-cell Therapy in T-cell Acute Lymphoblastic Leukemia

Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

Pre-transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy followed by Haploidentical HSCT for Relapsed/Refractory Acute Lymphoblastic Leukemia

CD22 CAR T-cell Therapy in Refractory or Relapsed B Acute Lymphoblastic Leukemia

High Efficacy and Safety of Low Dose CD19-directed CAR-T-cell Therapy in 51 Refractory or Relapsed B Acute Lymphoblastic Leukemia Patients

A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer